Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second half of 2024  Plans to...

Related Keywords

United States ,Seattle ,Washington ,American ,Mark Litton ,Hans Moebius ,Julie Rathbun ,Athira Pharma ,Securities Exchange ,Linkedin ,Motor Neurone Disease Association ,Nasdaq ,Exchange Commission ,Alzheimer Association International Congress ,Athira Pharma Inc ,Amyotrophic Lateral Sclerosis Consortium ,American Association Of Neurology ,Twitter ,Instagram ,Management Team ,Facebook ,Chief Executive Officer ,Chief Medical Officer ,Senior Scientific Advisor ,Pipeline Outlook ,Label Extension ,American Association ,Association International Congress ,Senior Scientific ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Media Contact ,Markets ,